Metastatic Breast Cancer
Conditions
Keywords
breast cancer, eribulin, nivolumab, immunotherapy, immune checkpoint inhibitor, metastatic breast cancer, PD-1
Brief summary
Cancer therapeutics such as chemotherapy may modulate tumor/immune-system interactions in favor of the immune system. Chemotherapy can result in tumor cell death with a resultant increase in tumor antigen delivery to antigen-presenting cells. Therefore, combining immunotherapy (Nivolumab) with chemotherapy (Eribulin) is a promising anti-cancer strategy.
Interventions
DRUGNivolumab
Nivolumab 360mg on D1 every 3 weeks Eribulin 1.4mg/m2 on D1, 8 every 3 weeks
Sponsors
Seoul National University Bundang Hospital
Korean Cancer Study Group (KCSG)
Eisai Korea Inc.
Ono pharmaceutical Korea
Seoul National University Hospital
Study design
Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Intervention model description
ER+/HER2- BC cohort: 45 pts ER-/HER2- (Triple negative) BC cohort: 45 pts
Eligibility
Sex/Gender
FEMALE
Age
20 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Provision of informed consent prior to any study specific procedures * Age 20 years or older * ECOG performance status(PS) 0 or 1 * Histologically confirmed stage IV or recurrent breast cancer * HER2 negative disease: not eligible for anti-HER2 therapy \* HER2 negative \[IHC 0, 1+ or IHC 2+ with corresponding ISH non-amplified or ratio less than 2.0 or ISH non-amplified ratio less than 2.0\] as per ASCO-CAP HER2 guideline recommendations 2013 (ASCO-CAP) * Patients previously treated with anthracycline and/or taxane unless contraindicated; Patients who received anthracycline and/or taxane based chemotherapy in either the neoadjuvant, adjuvant or metastatic setting and experienced disease progression on or after taxane-based chemotherapy in the metastatic setting * No more than 3 prior lines of cytotoxic chemotherapy for metastatic disease; patients who experienced disease recurrence within 1 year after completion of (neo)adjuvant anthracycline and taxane-based chemotherapy will be counted as 1 prior line of treatment.; hormonal therapy will not be counted as a prior line of treatment * Measurable disease according to RECIST v 1.1.
Exclusion criteria
* Previous treatment with eribulin mesylate or any anti-PD-1, PD-L1, or PD-L2 * Active autoimmune disease that has required systemic treatment in the past 2 years (ie, with use of disease modifying agents, corticosteroids, or immunosuppressive drugs). Replacement therapy (eg, thyroxine, insulin, or physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency, etc) is not considered a form of systemic treatment. * Known central nervous system (CNS) disease, except for those subjects with treated brain metastasis who are stable for at least 1 month, having no evidence of progression or hemorrhage after treatment and no ongoing requirement for corticosteroids, as ascertained by clinical examination and brain imaging (magnetic resonance imaging \[MRI\] or computed tomography \[CT\]) during the screening period * Known history of human immunodeficiency virus (HIV) positive * Known active hepatitis B or hepatitis C (eg, HCV RNA detected) * Any other malignancy that required treatment or has shown evidence of recurrence (except for nonmelanoma skin cancer, or histologically confirmed complete excision of carcinoma in situ) during the 3 years prior to enrollment in this study * History of significant cardiovascular disease * Hypersensitivity to the active substance or any other excipients of the eribulin mesylate drug product, or to nivolumab * Scheduled for major surgery during the study * Has a diagnosis of immunodeficiency or is receiving systemic steroid therapy or any other form of immunosuppressive therapy within 7 days prior to the first dose of trial treatment. The use of physiologic doses of corticosteroids may be allowed * Has a history of (non-infectious) pneumonitis that required steroids or current pneumonitis * Has a history of interstitial lung disease * Has received a live-virus vaccination within 30 days of planned start of study therapy. Seasonal flu vaccines that do not contain live virus are permitted.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| 6 months progression-free survival (PFS) rate | 6 months |
Secondary
| Measure | Time frame |
|---|---|
| Objective response rate by RECIST criteria v 1.1 | 2 years |
| Overall survival (OS) | 2 years (upto 5 years) |
| Incidence Rate of each Toxicity by CTCAE 4.0 | 2 years (upto 5 years) |
| Clinical benefit rate by RECIST criteria v 1.1 (and iRECIST) | 2 years |
Countries
South Korea
Outcome results
None listed